Good evening :)
Place Order
Add to Watchlist

Nath Bio-Genes (I) Ltd

NATHBIOGEN

Nath Bio-Genes (I) Ltd

NATHBIOGEN
Consumer StaplesAgro Products
SmallcapWith a market cap of ₹382 cr, stock is ranked 2,024
Moderate RiskStock is 2.84x as volatile as Nifty
203.620.37% (+0.75)
203.620.37% (+0.75)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Consumer StaplesAgro Products
SmallcapWith a market cap of ₹382 cr, stock is ranked 2,024
Moderate RiskStock is 2.84x as volatile as Nifty
Scorecard

Performance

Low

Hasn't fared well - amongst the low performers

Valuation

Avg

Can be considered moderately valued vs the market

Growth

Low

Lagging behind the market in financials growth

Profitability

High

Showing good signs of profitability & efficiency

Entry point

Good

The stock is underpriced and is not in the overbought zone

Red flags

Low

No red flag found

How to use scorecard? Learn more

Consumer StaplesAgro Products
SmallcapWith a market cap of ₹382 cr, stock is ranked 2,024
Moderate RiskStock is 2.84x as volatile as Nifty

Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
9.350.630.99%
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
51.6710.261.46%

Forecast & Ratings

Detailed Forecast 
Forecast data is currently unavailable for this stock

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Nath Bio-Genes (India) is engaged in hybrid seed business and production, processing and marketing of hybrid and genetically modified (GM) seeds

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

Forecasts

Price

Revenue

Earnings

Income

Balance Sheet

Cash Flow

Income Statement

Loading...

Financial YearFY 2022FY 2023FY 2024TTM
Total Revenue280.21301.91336.70354.95
Raw Materialssubtract3.565.3112.26299.92
Power & Fuel Costsubtract1.071.391.13
Employee Costsubtract24.7823.3227.58
Selling & Administrative Expensessubtract89.99112.25139.47
Operating & Other expensessubtract210.53110.26102.23
Depreciation/Amortizationsubtract3.083.013.263.40
Interest & Other Itemssubtract10.6410.219.209.13
Taxes & Other Itemssubtract3.951.131.951.60
EPS-35.4618.4320.8521.52
DPS2.002.002.002.00
Payout ratio0.110.100.09

Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2021

Annual report

PDF

Investor Presentation

Jun 24PDF
FY 2022

Annual report

PDF

Investor Presentation

May 30PDF
Feb 14PDF
Nov 1PDF
Aug 10PDF
FY 2023

Annual report

PDF

Investor Presentation

Apr 22PDF
Feb 14PDF
Oct 20PDF
Aug 13PDF
FY 2024

Annual report

PDF

Investor Presentation

Aug 10PDF
 

Peers & Comparison

Comparing 3 stocks from 
Consumer StaplesAgro Products

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Nath Bio-Genes (I) Ltd9.650.630.99%
Godrej Agrovet Ltd41.225.081.30%
Gujarat Ambuja Exports Ltd17.252.150.27%
Sanstar Ltd33.958.93

Price Comparison

Compare NATHBIOGEN with any stock or ETF
Compare NATHBIOGEN with any stock or ETF
NATHBIOGEN
Loading...

Shareholdings

Promoter Holdings Trend

Total Promoter Holding

Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding

Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Institutional Holdings Trend

Decreased Total Retail Holding

Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has decreased by 1.68%

Foreign Institutional Holding

Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding45.60%4.37%0.00%0.19%49.85%

Dec 2023

Mar 2024

Jun 2024

Sep 2024

Shareholding History

JunSepDec '23MarJunSep0.08%0.22%0.32%0.27%0.22%0.19%

Mutual Funds Holding Trend

Mutual Fund Holding

Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

Top 1 Mutual Funds holding Nath Bio-Genes (I) Ltd


Funds (Top 1)Market-cap heldWeight3M holding changePortfolio rank
(3M change)
Aditya Birla Sun Life Pure Value Fund - Growth - Direct Plan

Growth
4.1274%0.25%-0.02%37/87 (0)

Compare 3-month MF holding change on Screener

Insider Trades & Bulk Deals

Loading...

smallcases

Looks like this stock is not in any smallcase yet.

Events

Dividend Trend

No dividend trend available

Dividends

Corp. Actions

Announcements

Legal Orders

Upcoming Dividends

No upcoming dividends are available

Past Dividends

Cash Dividend

Ex DateEx DateAug 9, 2024

Final
Final | Div/Share: ₹2.00

Dividend/Share

2.00

Ex DateEx Date

Aug 9, 2024

Cash Dividend

Ex DateEx DateJul 4, 2023

Final
Final | Div/Share: ₹2.00

Dividend/Share

2.00

Ex DateEx Date

Jul 4, 2023

Cash Dividend

Ex DateEx DateJun 23, 2022

Final
Final | Div/Share: ₹2.00

Dividend/Share

2.00

Ex DateEx Date

Jun 23, 2022

Cash Dividend

Ex DateEx DateAug 18, 2021

Final
Final | Div/Share: ₹2.00

Dividend/Share

2.00

Ex DateEx Date

Aug 18, 2021

News & Opinions
Earnings
Nath Bio-Genes (India) consolidated net profit declines 26.49% in the September 2024 quarter

Net profit of Nath Bio-Genes (India) declined 26.49% to Rs 1.11 crore in the quarter ended September 2024 as against Rs 1.51 crore during the previous quarter ended September 2023. Sales rose 42.62% to Rs 32.19 crore in the quarter ended September 2024 as against Rs 22.57 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales32.1922.57 43 OPM %14.9422.06 - PBDT1.912.61 -27 PBT1.091.85 -41 NP1.111.51 -26 Powered by Capital Market - Live

1 month agoCapital Market - Live
Earnings
Nath Bio-Genes (India) standalone net profit rises 79.50% in the September 2024 quarter

Net profit of Nath Bio-Genes (India) rose 79.50% to Rs 2.89 crore in the quarter ended September 2024 as against Rs 1.61 crore during the previous quarter ended September 2023. Sales rose 42.62% to Rs 32.19 crore in the quarter ended September 2024 as against Rs 22.57 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales32.1922.57 43 OPM %20.3822.60 - PBDT3.692.72 36 PBT2.861.96 46 NP2.891.61 80 Powered by Capital Market - Live

1 month agoCapital Market - Live
Corporate
Nath Bio-Genes (India) announces board meeting date

Nath Bio-Genes (India) will hold a meeting of the Board of Directors of the Company on 23 October 2024.Powered by Capital Market - Live

1 month agoCapital Market - Live
Earnings
Nath Bio-Genes (India) consolidated net profit declines 0.24% in the June 2024 quarter

Net profit of Nath Bio-Genes (India) declined 0.24% to Rs 33.35 crore in the quarter ended June 2024 as against Rs 33.43 crore during the previous quarter ended June 2023. Sales rose 3.66% to Rs 243.88 crore in the quarter ended June 2024 as against Rs 235.28 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales243.88235.28 4 OPM %14.9815.74 - PBDT34.4334.38 0 PBT33.6033.62 0 NP33.3533.43 0 Powered by Capital Market - Live

4 months agoCapital Market - Live
Corporate
Nath Bio-Genes (India) announces board meeting date

Nath Bio-Genes (India) will hold a meeting of the Board of Directors of the Company on 7 August 2024.Powered by Capital Market - Live

4 months agoCapital Market - Live

Dividend paying stocks 2022: 5 stocks to turn ex-dividend tomorrow

2 years agoLivemint

Nath Bio-Genes (India) standalone net profit declines 59.14% in the September 2021 quarter

3 years agoBusiness Standard

Minda Corporation Ltd leads gainers in ‘A’ group

3 years agoBusiness Standard

Top stocks in focus: Aarey Drugs & Pharmaceuticals, Fortis Malar Hospitals, Nath Bio-Genes, Pricol, Gujarat Alkalies and Chemicals

3 years agoIndia Infoline

Nath Bio-Genes (India) standalone net profit rises 8.85% in the June 2021 quarter

3 years agoBusiness Standard